COVID-19 患者重症监护中细菌和真菌感染性血流感染的发生率：令人震惊的“附带效应”。
Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect".
机构信息
National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
出版信息
J Glob Antimicrob Resist. 2020 Dec;23:290-291. doi: 10.1016/j.jgar.2020.10.004. Epub 2020 Oct 29.
Abstract
• COVID-19 patients have an exaggerated risk of acquiring BSI during ICU stay. • The incidence of ICU-acquired BSI in COVID-19 patients is higher than that reported in European ICUs in the pre-COVID-19 period. • The commonest aetiological agents of BSI were intestinal commensals. • A high rate of acquisition of VRE colonisation was observed.
摘要
• COVID-19 患者在 ICU 住院期间获得 BSI 的风险增加。
• COVID-19 患者 ICU 获得性 BSI 的发生率高于 COVID-19 前欧洲 ICU 报告的发生率。
• BSI 的最常见病原体为肠道共生菌。
• 观察到 VRE 定植的高发生率。
相似文献
1
Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect".
J Glob Antimicrob Resist. 2020 Dec;23:290-291. doi: 10.1016/j.jgar.2020.10.004. Epub 2020 Oct 29.
2
Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88. doi: 10.1017/ice.2020.368. Epub 2020 Jul 24.
3
Central line-associated bloodstream infections among critically-ill patients in the era of bundle care.
J Microbiol Immunol Infect. 2017 Jun;50(3):339-348. doi: 10.1016/j.jmii.2015.07.001. Epub 2015 Jul 31.
4
Incidence of risk factors for bloodstream infections in patients with major burns receiving intensive care: A retrospective single-center cohort study.
Burns. 2018 Jun;44(4):784-792. doi: 10.1016/j.burns.2017.12.009. Epub 2018 Feb 1.
5
Nosocomial methicillin-resistant Staphylococcus aureus bacteremia in incarcerated patients with severe COVID-19 infection.
Am J Infect Control. 2020 Dec;48(12):1568-1569. doi: 10.1016/j.ajic.2020.09.005. Epub 2020 Sep 20.
6
A Retrospective Study of Coinfection of SARS-CoV-2 and Streptococcus pneumoniae in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center.
Med Sci Monit. 2020 Nov 14;26:e928754. doi: 10.12659/MSM.928754.
7
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors.
Clin Microbiol Infect. 2021 Mar;27(3):451-457. doi: 10.1016/j.cmi.2020.10.021. Epub 2020 Oct 24.
8
The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections.
J Microbiol Immunol Infect. 2018 Jun;51(3):401-410. doi: 10.1016/j.jmii.2017.08.016. Epub 2017 Sep 6.
9
Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball.
J Glob Antimicrob Resist. 2020 Dec;23:398-400. doi: 10.1016/j.jgar.2020.11.004. Epub 2020 Nov 23.
10
Bloodstream infections and antimicrobial resistance patterns in a South African neonatal intensive care unit.
Paediatr Int Child Health. 2014 May;34(2):108-14. doi: 10.1179/2046905513Y.0000000082. Epub 2013 Dec 6.
引用本文的文献
1
Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review.
Pathogens. 2025 May 10;14(5):466. doi: 10.3390/pathogens14050466.
2
Bloodstream Infections in Critical Care Units in England, April 2017 to March 2023: Results from the First Six Years of a National Surveillance Programme.
Microorganisms. 2025 Jan 16;13(1):183. doi: 10.3390/microorganisms13010183.
3
Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.
BMC Infect Dis. 2025 Jan 3;25(1):13. doi: 10.1186/s12879-024-10420-1.
4
Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.
Mycoses. 2024 Oct;67(10):e13798. doi: 10.1111/myc.13798.
5
The role of SARS-COV-2 infection in promoting abnormal immune response and sepsis: A comparison between SARS-COV-2-related sepsis and sepsis from other causes.
Infect Med (Beijing). 2023 Apr 28;2(3):202-211. doi: 10.1016/j.imj.2023.04.006. eCollection 2023 Sep.
6
Coronavirus disease 2019 (COVID-19) impact on central-line-associated bloodstream infections (CLABSI): a systematic review.
Infect Prev Pract. 2023 Oct 13;5(4):100313. doi: 10.1016/j.infpip.2023.100313. eCollection 2023 Dec.
7
Bloodstream Infections in Intensive Care Unit during Four Consecutive SARS-CoV-2 Pandemic Waves.
Antibiotics (Basel). 2023 Sep 14;12(9):1448. doi: 10.3390/antibiotics12091448.
8
Research on SARS-COV-2 pandemic: a narrative review focused on the Italian contribution.
J Anesth Analg Crit Care. 2021 Nov 17;1(1):14. doi: 10.1186/s44158-021-00017-4.
9
Fungal-Bacterial Co-Infections and Super-Infections among Hospitalized COVID-19 Patients: A Systematic Review.
J Fungi (Basel). 2023 May 23;9(6):598. doi: 10.3390/jof9060598.
10
Invasive Candidiasis in Patients with Solid Tumors: A Single-Center Retrospective Study.
Int J Gen Med. 2023 Jun 13;16:2419-2426. doi: 10.2147/IJGM.S411006. eCollection 2023.
本文引用的文献
1
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.
2
Bacterial and fungal infections in COVID-19 patients: A matter of concern.
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1124-1125. doi: 10.1017/ice.2020.156. Epub 2020 Apr 22.
3
Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck.
Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745. doi: 10.1017/ice.2020.69.
4
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55. doi: 10.1111/1469-0691.12427.
5
Management of multidrug-resistant organisms in health care settings, 2006.
Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93. doi: 10.1016/j.ajic.2007.10.006.
Zotero 插件